Webinar | August 23, 2023

Optimizing Oncology Trials To Generate High-Quality Data For Regulatory Decision-Making

The preliminary FDA directives pertaining to patient-reported outcomes measures (PROMS) within cancer trials are ushering in a paradigm shift in the blueprinting and execution of Clinical Outcome Assessment measurement approaches in the domain of oncology research.

Drawing from his profound expertise, Signant Health's Clinical Vice President of Internal Medicine, Anthony T. Everhart, MD, imparts invaluable perspectives on crafting effective measurement strategies in oncological frameworks. Furthermore, he expounds on the strategic utilization of decentralized methodologies to enhance the trial engagement journey for both patients and trial sites, thereby enriching the overall research experience.

Watch Episode 3 of Signant’s scientific video series, Clinical Viewpoints, for key takeaways from the recent FDA guidance on the use of COA and PROMS in oncology trials and other additional insights surrounding the topic.

access the Webinar!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader